Meril Life Sciences has introduced the first ever indigenously designed and manufactured Transcatheter Aortic Heart Valve(TAVR) – Myval. With this launch, Meril, a global medical devices company becomes the First Indian Company to make Transcatheter Aortic Heart Valve Replacement (TAVR) Therapy commercially available on the world stage.

Transcatheter Aortic Valve Replacement (TAVR) is an established treatment modality for patients who are at a high risk or unwilling to undergo open heart valve replacement surgery. TAVR is aminimally invasive procedure in which the doctor places a replacement valve into the patient’s native diseased valve via a catheter inserted through the femoral artery (large artery in groin). This is an alternative way to replace diseased valves without undergoing traditional open heart procedure (which some patients may not tolerate well).

Commenting on the approval, Sanjeev Bhatt (Vice President-Corporate Strategy, Meril Life Sciences) said, “Meril has always been dedicated towards design and development of novel, clinically relevant, state-of-the-art and best-in-class devices to alleviate human suffering and improve quality of life. The launch of indigenously developed Myval Transcatheter Heart Valve technology is an assertion of this fundamental belief. For us, it is a proud moment to be the first Indian company to commercially make this therapy available in the country.”

“The Myval-TAVR technology has been developed after six years of extensive research and is backed by robust bench testing, pre-clinical and clinical data. We are committed to take this technology to over 100 countries and benefit thousands of patients across the globe,” Dr P K Minocha (Director, Research & Development, Meril Life Sciences) said.

Dr Ashok Seth, Chairman of Fortis Escorts Heart Institute, said: “As the Principal Investigator of the clinical trial of MyvalTranscatheter Aortic Heart Valve, it is heartening to note that the device has been proven to be safe and effective as required by the regulatory standards of India.  The development of this valve, which is implanted non-surgically through a catheter is also a great achievement for the ‘Made in India’ initiative that such an important R&D has happened from India in a field which till now has been dominated by only American devices.”

“The regulatory approval of the indigenous Myval provides genuine hope for thousands of patients with Aortic Stenosis in India and Asia, who were considered risky for surgery and can now undergo safer Transcatheter Aortic Valve Replacement through non-surgical catheter-based treatment,” he stated.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.